Skip to main content
Enwei Pharmaceutical Co., Ltd. logo

Enwei Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301331 ISIN · CNE100005LC7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2025-10-29 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301331

About Enwei Pharmaceutical Co., Ltd.

https://www.enwei.com.cn

Enwei Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of medicinal products, specializing in Chinese patent medicines and chemical drugs. The company is primarily known for its gynecological health solutions, most notably the Jie Er Yin brand. Its diverse product range covers therapeutic categories such as pediatrics, dermatology, and respiratory care. By combining traditional Chinese medicine with modern pharmacological standards, the company produces various dosage forms including lotions, capsules, and granules. The organization emphasizes clinical efficacy and quality management, targeting a wide range of healthcare needs through ongoing innovation in formulation and drug delivery systems.

Recent filings

Filing Released Lang Actions
北京金杜（成都）律师事务所关于恩威医药股份有限公司2023年限制性股票激励计划调整、第二个归属期归属条件成就及部分限制性股票作废事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the adjustment, vesting conditions achievement, and cancellation of certain restricted stocks under a 2023 restricted stock incentive plan of a listed company. It references specific regulatory frameworks such as the Securities Law, Company Law, and stock exchange listing rules, and discusses approvals by the company's board and shareholders. The document is focused on legal compliance and authorization related to stock incentive plans, not on financial results, earnings, or general corporate governance changes. It is not a financial report, earnings release, or management discussion, but a legal opinion on stock incentive plan adjustments and related corporate actions. This type of document fits best under the category of Regulatory Filings (RNS) as it is a regulatory announcement/legal opinion related to compliance and corporate actions, not a full audit report or annual report. The document length (7799 characters) and content confirm it is not a brief announcement or a full financial report but a detailed legal opinion letter.
2025-10-29 Chinese
关于调整2023年限制性股票激励计划第二类限制性股票授予价格的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the adjustment of the 2023 restricted stock incentive plan's second category restricted stock grant price by Enwei Pharmaceutical Co., Ltd. It details board and committee meetings, approvals, legal opinions, and the impact of the adjustment on the company. The document is a formal announcement of changes related to stock incentive plans, specifically about the adjustment of grant prices and quantities, and does not contain financial statements or detailed financial performance data. It is not a full annual or interim report, nor is it a regulatory filing or certification. The content fits best under a capital/financing update category as it relates to equity incentive plan adjustments affecting capital structure and stock grants.
2025-10-29 Chinese
2025年三季度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as the "2025 Third Quarter Report" of the company 恩威医药股份有限公司. It contains detailed financial data including revenue, net profit, cash flow, earnings per share, and balance sheet items as of September 30, 2025. The presence of comprehensive financial statements and analysis for a quarterly period indicates this is a quarterly financial report. The document length is substantial (15,000 characters), and it includes actual financial data rather than just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2025-10-29 Chinese
上海荣正企业咨询服务（集团）股份有限公司关于恩威医药股份有限公司2023年限制性股票激励计划第二期归属条件成就相关事项之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" related to the 2023 Restricted Stock Incentive Plan of Enwei Pharmaceutical Co., Ltd. It discusses detailed conditions, approvals, and achievements related to the second phase of the restricted stock incentive plan, including board meeting resolutions, shareholder approvals, and compliance with regulatory requirements. The content is focused on the financial advisory opinion regarding the stock incentive plan's vesting conditions and related corporate governance matters. It is not a full annual or interim financial report, nor is it a simple announcement or proxy solicitation. The document is a standalone advisory report on a specific financial incentive plan, which fits the category of Audit Report / Information (AR) as it includes independent financial advisor opinions and compliance verification related to accounting and regulatory standards for the incentive plan. The document length and detail confirm it is a full report, not just an announcement or certification.
2025-10-29 Chinese
关于2023年限制性股票激励计划第二期归属条件成就的公告
Remuneration Information Classification · 95% confidence The document is a detailed announcement from a company regarding the achievement of vesting conditions for the second phase of a 2023 restricted stock incentive plan. It includes specifics about the number of shares vested, the price adjustments, the approval process by the board and committees, legal and financial advisor opinions, and the impact on the company's financials and share structure. The document is not a full annual or interim report, nor is it a simple announcement of a report publication. It is not related to earnings releases, M&A, or voting results. It focuses on management compensation and stock incentive plans, which aligns with Remuneration Information filings. However, since it is specifically about stock incentive plan vesting and related approvals, it fits best under the category of Remuneration Information (DEF 14A) which covers executive and director compensation and stock incentive disclosures.
2025-10-29 Chinese
提名与薪酬委员会关于2023年限制性股票激励计划第二期可归属激励对象名单的核查意见
Remuneration Information Classification · 95% confidence The document is a formal opinion from the Nomination and Remuneration Committee regarding the verification of the list of eligible recipients for the second phase of a 2023 restricted stock incentive plan. It references compliance with company law, securities law, stock exchange listing rules, and the company's articles of association. The content focuses on the approval and verification of stock incentive recipients and their eligibility, which relates to remuneration and compensation matters. There is no financial data, earnings information, or report publication mentioned. The document is not an announcement of a report but a committee opinion on compensation-related matters. Therefore, the most appropriate classification is Remuneration Information (DEF 14A).
2025-10-29 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.